New Two-Pronged attack on uterine cancer aims to spare women surgery
NCT ID NCT07349641
Summary
This study is testing if adding a weekly weight-loss injection (tirzepatide) to a hormone-releasing IUD can better treat early-stage uterine cancer or a pre-cancerous condition in women who are overweight or obese. The goal is to see if this combination can eliminate cancer cells from the uterus, potentially offering a non-surgical treatment option. It will involve about 55 women and compare results to historical data from women who only received the IUD.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern University
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.